Chemotherapy Induced Peripheral Neuropathy (CIPN)CIPNNCT07712302
Effect of GMI With and Without NM on LE in Cancer Patients With CIPN
A study testing Graded Motor Imagery and Neural Mobilization in people with Chemotherapy Induced Peripheral Neuropathy (CIPN) and Cancer, run by University of Faisalabad at 1 site in Pakistan.
Trial summary
The goal of this interventional study is to learn if graded motor imagery with or without added neural mobilization can treat chemotherapy induced nerve related symptoms in lower limbs of cancer patients. Read more about this study
- Who is it for?
- Ages 31 to 65 years
- Conditions the study is for
- Chemotherapy Induced Peripheral Neuropathy (CIPN), Cancer
- What is being tested?
- Graded Motor Imagery and Neural Mobilization
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 48 participants
- Where
- 1 sitePakistan
- Study dates
- 1 Mar 2025to 6 Jun 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 31 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Both male and female
- Age ranging from 31 to 65 years
- Diagnosed cancer patients (stage 1 to 3, cancer of any kind)
- Chemotherapy sessions (antineoplastic drugs) - at least 1 session
- Presence of glove and stocking peripheral neuropathy
- LANSS score greater than 12
- Agreed to give complete follow-up
Who cannot join
- Any co-morbid conditions that can cause peripheral neuropathy e.g. diabetes, chronic kidney failure
- Any trauma history that can cause peripheral neuropathic symptoms
- Pre-existing nerve entrapment syndromes
- Diagnosed stage 4 cancer patients
- Cancer patients taking palliative chemotherapy
Trial locations and contacts
1 site in 1 country.
Pakistan1 site
The University of Faisalabad
Faisalābad, Punjab Province, 38000
About this study
Official title: Effect of Graded Motor Imagery With and Without Neural Mobilization on Lower Extremity in Cancer Patients With Chemotherapy-induced Peripheral Neuropathy
The goal of this interventional study is to learn if graded motor imagery with or without added neural mobilization can treat chemotherapy induced nerve related symptoms in lower limbs of cancer patients. The main questions it aims to answer are:
- Does graded motor imagery yields any added effects in relieving nerve related symptoms due to chemotherapy in lower limbs of cancer patients to the effects of nerve mobilization? Researchers will compare the effects of graded motor imagery as a standalone therapy (Group A) to the effects of graded motor imagery with nerve mobilization (Group B) Participants will take treatment sessions according to their allocated group, two sessions per week for six weeks.
- Being tested
- Graded Motor Imagery, Neural Mobilization
- Keywords
- Cancer, Neural Mobilization, Graded Motor Imagery, Neuropathic pain, Nerve gliding, Chemotherapy Induced Peripheral Neuropathy, Sensory Ataxia
- Medical subject headings
- Neoplasms, Neuralgia, Ataxia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Graded Motor ImageryOther
Graded motor imagery is a series of three steps. The first step, lateral recognition, includes graded left and right judgment exercises. The second step involves imagining the performance of movements and the third, and last step involves performing movements in front of a mirror.
Neural MobilizationOther
Nerve mobilization allows movement between structures of nervous system and its surrounding areas. It is used to mobilize the nervous system and maintain equilibrium inside the nervous system as well as in structures present in its surroundings.
| Study group | Role | What they receive |
|---|---|---|
| Group A - Graded Motor Imagery | Experimental | Graded motor imagery sessions were provided twice a week for six weeks. Each GMI phase lasted for two weeks. Receives: Other: Graded Motor Imagery |
| Group B - Grade Motor Imagey with Neural Mobilization | Active comparator | Graded motor imagery with neural mobilization sessions were provided twice a week for six weeks. Receives: Other: Graded Motor Imagery; Other: Neural Mobilization |
What is being measured
The primary outcome is the main question the study is designed to answer.
LANSS
Leeds Assessment of Neuropathic Symptoms and Sign
Measured: Baseline, week 3 (mid-intervention), week 6 (post intervention)
Secondary outcomes (2)
Romberg Test
Quantitative version of Romberg Test
Measured: Baseline, week 6 (post-intervention)
EORTC-QLQ-CIPN20
European Organization of Research and Treatment of Cancer-Quality of Life Questionnaire-Chemotherapy Induced Peripheral Neuropathy 20
Measured: Baseline, week 6 (post-intervention)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jul 2026
- Study start1 Mar 2025
- Primary completion6 Jun 2025
- Study completion6 Jun 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chemotherapy Induced Peripheral Neuropathy (CIPN)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Group A was given graded motor imagery Group B was given graded motor imagery with neural mobilization
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 48 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Faisalabad
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07712302
- Sponsor's protocol ID
- TUF/IRB/98/2025
- Acronym
- CIPN
- Status last verified
- Jul 2026
- First submitted
- 14 Jul 2026
- Last updated
- 17 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 17 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Graded Motor Imagery With and Without Neural Mobilization on Lower Extremity in Cancer Patients With Chemotherapy-induced Peripheral Neuropathy
- ClinicalTrials.gov ID
- NCT07712302
- Acronym / sponsor ID
- CIPN / TUF/IRB/98/2025
- Keywords
- Cancer, Neural Mobilization, Graded Motor Imagery, Neuropathic pain, Nerve gliding, Chemotherapy Induced Peripheral Neuropathy, Sensory Ataxia
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 48 participants (actual)
- Lead sponsor
- University of FaisalabadUniversity, hospital or other
- Study start
- 1 Mar 2025 (actual)
- Primary completion
- 6 Jun 2025 (actual)
- Study completion
- 6 Jun 2025 (actual)
- First posted
- 17 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this interventional study is to learn if graded motor imagery with or without added neural mobilization can treat chemotherapy induced nerve related symptoms in lower limbs of cancer patients. The main questions it aims to answer are:
- Does graded motor imagery yields any added effects in relieving nerve related symptoms due to chemotherapy in lower limbs of cancer patients to the effects of nerve mobilization? Researchers will compare the effects of graded motor imagery as a standalone therapy (Group A) to the effects of graded motor imagery with nerve mobilization (Group B) Participants will take treatment sessions according to their allocated group, two sessions per week for six weeks.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
- Model description
- Group A was given graded motor imagery Group B was given graded motor imagery with neural mobilization
| Arm | Type | Receives |
|---|---|---|
| Group A - Graded Motor Imagery | Experimental | Other: Graded Motor ImageryGraded motor imagery sessions were provided twice a week for six weeks. Each GMI phase lasted for two weeks. |
| Group B - Grade Motor Imagey with Neural Mobilization | Active comparator | Other: Graded Motor Imagery, Other: Neural MobilizationGraded motor imagery with neural mobilization sessions were provided twice a week for six weeks. |
Who may qualify
- Ages
- 31 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Both male and female
- Age ranging from 31 to 65 years
- Diagnosed cancer patients (stage 1 to 3, cancer of any kind)
- Chemotherapy sessions (antineoplastic drugs) - at least 1 session
- Presence of glove and stocking peripheral neuropathy
Key exclusion criteria (5 listed)
- Any co-morbid conditions that can cause peripheral neuropathy e.g. diabetes, chronic kidney failure
- Any trauma history that can cause peripheral neuropathic symptoms
- Pre-existing nerve entrapment syndromes
- Diagnosed stage 4 cancer patients
- Cancer patients taking palliative chemotherapy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Graded Motor ImageryGraded motor imagery is a series of three steps. The first step, lateral recognition, includes graded left and right judgment exercises. The second step involves imagining the performance of movements and the third, and last step involves performing movements in front of a mirror. | Other | Group A - Graded Motor Imagery, Group B - Grade Motor Imagey with Neural Mobilization |
| Neural MobilizationNerve mobilization allows movement between structures of nervous system and its surrounding areas. It is used to mobilize the nervous system and maintain equilibrium inside the nervous system as well as in structures present in its surroundings. | Other | Group B - Grade Motor Imagey with Neural Mobilization |
Primary outcome
LANSS
Time frame: Baseline, week 3 (mid-intervention), week 6 (post intervention)
Leeds Assessment of Neuropathic Symptoms and Sign
2 secondary outcomes
Romberg Test
Time frame: Baseline, week 6 (post-intervention)
EORTC-QLQ-CIPN20
Time frame: Baseline, week 6 (post-intervention)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jul 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Chemotherapy Induced Peripheral Neuropathy (CIPN)
Not yet recruiting
Continuous Controlled Cooling for Prevention of Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy Induced Peripheral Neuropathy (CIPN)
RecruitingObservational study
Relationship Between Great Toe Strength And Symptoms of Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Chemotherapy-induced Peripheral Neuropathy (CIPN), Healthy
Not yet recruiting
The Effect of Aerobic and Resistance Training With and Without Neurodynamic Exercises on Chemotherapy-induced Peripheral Neuropathy Symptoms and Associated Neuro-immune Mechanisms
Chemotherapy Induced Peripheral Neuropathy (CIPN)
RecruitingPhase 2
Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN)
Chemotherapy-induced Peripheral Neuropathy, Chemotherapy-induced Neuropathic Pain
Not yet recruiting
AYUrvedic Foot Massage for Symtoms of Taxane-induced Peripheral nEuroPathy
Chemotherapy-induced Peripheral Neuropathy (CIPN)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Graded Motor Imagery and Neural Mobilization in people with Chemotherapy Induced Peripheral Neuropathy (CIPN) and Cancer, run by University of Faisalabad at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
LANSS (time frame: Baseline, week 3 (mid-intervention), week 6 (post intervention)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jul 2026.